Neogen Chemicals' board of directors has approved raising funds up to ₹600 crore in Indian/foreign currency through qualified institutional placements (QIP) and other eligible securities. As reported by Business Standard, the board meeting held on July 24, 2026 approved the fund raising via issue of any instrument or security(ies) including equity shares, or any other eligible securities or any combination thereof, in one or more tranche. This approval represents a significant capital infusion strategy that could substantially impact the company's future growth trajectory, capital structure, and expansion plans.
Neogen Chemicals' shares experienced a decline of 2.32 percent in the previous trading session, closing at ₹2,105.20 on the National Stock Exchange (NSE). As reported by Moneycontrol, this movement occurred ahead of the highly anticipated board meeting scheduled for tomorrow. The company's shares have a market capitalization of ₹5,764.39 crore, and the decline indicates some apprehension or profit-booking among investors ahead of the crucial announcements. According to latest trading data from Kotak Neo, the stock opened at ₹2,155.3 and closed at the same level, with intraday trading ranging between ₹2,080.10 and ₹2,181.80, giving it an average price of ₹2,130.95 for the day. However, as of July 23, 2026, the stock was trading at ₹2,088, down by ₹17.19 from its previous closing, with the stock fluctuating between ₹2,078.1 and ₹2,141 during the session.
According to Moneycontrol reports, Neogen Chemicals posted a consolidated net profit of ₹11.36 crore for the quarter ended March 2026, marking a substantial year-on-year increase compared to ₹2.36 crore recorded in the corresponding quarter of the previous fiscal year (March 2025). The company's consolidated revenue from operations reached ₹246.56 crore in March 2026, up from ₹202.82 crore in March 2025. The Earnings Per Share (EPS) for the March 2026 quarter stood at ₹4.32, showing significant improvement from ₹0.91 in March 2025. As per Kotak Neo data, the company reported a 4.3% quarter-on-quarter increase in consolidated revenues for Q3FY25, with 22.0% year-on-year growth, while expenses increased by 4.8% QoQ and 16.8% YoY.
As reported by Moneycontrol, for the full fiscal year ending March 2026, Neogen Chemicals reported a consolidated net profit of ₹28.47 crore, which was a decline from ₹34.63 crore in the preceding fiscal year (March 2025). However, the company's revenue for FY26 showed continued growth, reaching ₹861.96 crore, up from ₹777.56 crore in FY25. The company's Debt to Equity ratio as of March 2026 stood at 1.63, indicating an increasing reliance on borrowed capital, while its Return on Equity (ROE) for FY26 was recorded at 3.52 percent, reflecting the efficiency of generating profits from shareholders' equity.
Neogen Chemicals shares have demonstrated strong performance over the past year, with 69.7% growth over six months and 44.89% increase over the last year, as reported by Kotak Neo. The stock has recorded a 52-week high of ₹2,374 and a 52-week low of ₹966.70, with the current market price of ₹2,088 as of July 23, 2026. The company's market capitalization stands at ₹5,714.60 crore as of the latest trading session. According to latest market data, the stock has a PE ratio of 123.24 and P/B ratio of 370.61, while Mutual Fund shareholding stands at 15.77% as of July 22, 2026. The stock has achieved a return of 32.57% over the past year and 9.93% in the last month alone, indicating strong investor confidence despite recent volatility.
